AbbVie Inc. (ABBV) Stock Analysis
Falling Knife setup
Healthcare · Drug Manufacturers - General
Sell if holding. Engine flags exit at $207.00. Weak growth.
AbbVie is a global biopharmaceutical company with leadership positions in immunology, neuroscience, oncology, and aesthetics, commercializing products including Skyrizi, Rinvoq, Humira, Vraylar, and Botox. Three wholesale distributors (McKesson, Cardinal Health, Cencora) account... Read more
Sell if holding. Engine flags exit at $207.00. Weak growth. Chart setup: Death cross, below all MAs, RSI 39, MACD bearish. Score 5.4/10, moderate confidence.
Passes 6/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductSkyrizi and Rinvoq42%10-K Item 1A: 'Skyrizi and Rinvoq each represented greater than 10% of AbbVie's total net revenues and, in aggregate, these products accounted for approximately 42% of total net revenues in 2025'
- MEDIUMSuppliersingle-source suppliers10-K Item 1A: 'AbbVie uses raw materials and components in its pharmaceutical and biologic manufacturing processes that may be sourced from single suppliers'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine flags exit at $207.00. Weak growth. Chart setup: Death cross, below all MAs, RSI 39, MACD bearish. Prior stop was $193.07. Score 5.4/10, moderate confidence.
Take-profit target: $229.33 (+12.5% upside). Prior stop was $193.07. Stop-loss: $193.07.
Weak growth.
AbbVie Inc. trades at a P/E of 99.9 (forward 12.6). TrendMatrix value score: 6.2/10. Verdict: Sell.
39 analysts cover ABBV with a consensus score of 3.9/5. Average price target: $249.
What does AbbVie Inc. do?AbbVie is a global biopharmaceutical company with leadership positions in immunology, neuroscience, oncology, and...
AbbVie is a global biopharmaceutical company with leadership positions in immunology, neuroscience, oncology, and aesthetics, commercializing products including Skyrizi, Rinvoq, Humira, Vraylar, and Botox. Three wholesale distributors (McKesson, Cardinal Health, Cencora) account for substantially all U.S. pharmaceutical product sales; no single wholesaler exceeds 43% of gross U.S. revenues.